Literature DB >> 27356848

Triazole resistance in Aspergillus fumigatus isolates from patients with cystic fibrosis in Italy.

Anna Prigitano1, Maria Carmela Esposto1, Arianna Biffi2, Gabriella De Lorenzis3, Vincenza Favuzzi4, Raffaella Koncan5, Giuliana Lo Cascio6, Marisol Barao Ocampo7, Carla Colombo8, Giovanna Pizzamiglio9, Luisa Romanò1, Anna Maria Tortorano10.   

Abstract

BACKGROUND: Aspergillus fumigatus is frequently recovered from respiratory secretions of cystic fibrosis (CF) patients. Azole resistance has been increasingly reported.
OBJECTIVES: To assess the prevalence of azole resistance in A. fumigatus isolates from patients followed by two CF centers of northern Italy.
METHODS: 423 isolates (220 patients) were screened for azole resistance. Resistance was confirmed with the EUCAST method and cyp51A gene sequencing. Microsatellite genotyping was performed and results were compared with those of environmental resistant isolates.
RESULTS: No resistance was detected in one center, while 8.2% of the patients of the other center harbored resistant isolates. The TR34/L98H alteration in the cyp51A gene, present in seven cases, resulted associated with poor in-vitro activity of all tested azoles.
CONCLUSIONS: The environmental origin of the resistance seems to be probable since azole resistance was found also in naïve patients and an identical microsatellite genotype in clinical and environmental isolates was observed.
Copyright © 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aspergillus fumigatus; Azole resistance; Cystic fibrosis; Italy

Mesh:

Substances:

Year:  2016        PMID: 27356848     DOI: 10.1016/j.jcf.2016.06.006

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  11 in total

Review 1.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

Review 2.  Azole Resistance in Aspergillus fumigatus in Patients with Cystic Fibrosis: A Matter of Concern?

Authors:  A Hamprecht; F Morio; O Bader; P Le Pape; J Steinmann; E Dannaoui
Journal:  Mycopathologia       Date:  2017-06-26       Impact factor: 2.574

3.  Contemporary Gene Flow is a Major Force Shaping the Aspergillus fumigatus Population in Auckland, New Zealand.

Authors:  Greg A Korfanty; Lisa Teng; Nicole Pum; Jianping Xu
Journal:  Mycopathologia       Date:  2019-07-15       Impact factor: 2.574

Review 4.  Pharmacokinetics of Azole Antifungals in Cystic Fibrosis.

Authors:  Ryan M Rivosecchi; Palash Samanta; Moses Demehin; M Hong Nguyen
Journal:  Mycopathologia       Date:  2017-08-09       Impact factor: 2.574

5.  Development and Validation of a High-Resolution Melting Assay To Detect Azole Resistance in Aspergillus fumigatus.

Authors:  L Bernal-Martínez; H Gil; O Rivero-Menéndez; S Gago; M Cuenca-Estrella; E Mellado; A Alastruey-Izquierdo
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

Review 6.  Emerging Fungal Threats in Cystic Fibrosis.

Authors:  C Schwarz; P Eschenhagen; J P Bouchara
Journal:  Mycopathologia       Date:  2021-07-28       Impact factor: 2.574

7.  The fading boundaries between patient and environmental routes of triazole resistance selection in Aspergillus fumigatus.

Authors:  Jochem B Buil; Rasmus K Hare; Bas J Zwaan; Maiken C Arendrup; Willem J G Melchers; Paul E Verweij
Journal:  PLoS Pathog       Date:  2019-08-22       Impact factor: 6.823

8.  Azole Resistance in Aspergillus fumigatus: A Five-Year Follow Up Experience in a Tertiary Hospital With a Special Focus on Cystic Fibrosis.

Authors:  Hélène Guegan; Emilie Prat; Florence Robert-Gangneux; Jean-Pierre Gangneux
Journal:  Front Cell Infect Microbiol       Date:  2021-02-18       Impact factor: 5.293

9.  Caenorhabditis elegans-Based Aspergillus fumigatus Infection Model for Evaluating Pathogenicity and Drug Efficacy.

Authors:  Chukwuemeka Samson Ahamefule; Qijian Qin; Arome Solomon Odiba; Siqiao Li; Anene N Moneke; James C Ogbonna; Cheng Jin; Bin Wang; Wenxia Fang
Journal:  Front Cell Infect Microbiol       Date:  2020-06-26       Impact factor: 5.293

10.  Synergistic effects of dual antimicrobial combinations of synthesized N-heterocycles or MgO nanoparticles with nisin against the growth of Aspergillus fumigatus: In vitro study.

Authors:  Hamid Beyzaei; Mojtaba Mirzaei; Narjes Hasan Fakhrabadi; Behzad Ghasemi
Journal:  Vet Res Forum       Date:  2021-06-15       Impact factor: 1.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.